Innovent Highlights Bispecific Antibody Pipeline at ATS and ARVO 2026
SAN FRANCISCO and SUZHOU, China, May 18, 2026 Innovent Biologics presented new clinical and preclinical data from its next-generation...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
SAN FRANCISCO and SUZHOU, China, May 18, 2026 Innovent Biologics presented new clinical and preclinical data from its next-generation...
Palo Alto, California, United States | May 1, 2026 Kodiak Sciences Inc. has announced new clinical and pipeline advancements...
PALO ALTO, Calif., Feb. 4, 2026 —Kodiak Sciences Inc. announced that final end-of-study Phase 1b APEX clinical results evaluating...
